Hemispherx stock: buy or sell?

HEB stock price: $1.96 4.26% At close on September 6th, 2019

Updated on:
September 6th, 2019


Hemispherx ended on September/6 at $1.96 and skyrocketed an extraordinary 4.26%.

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States.

Should I buy Hemispherx stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to define your own trading strategy that fits your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, Hemispherx BioPharma stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean HEB will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Hemispherx BioPharma stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we found 1 rating published for HEB stock in the last 30 days.

Is HEB a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-22Maxim GroupBuyHold

Hemispherx stock analysis

Daily outlook

Hemispherx BioPharma skyrocketed an extraordinary 4.26% and closed at $1.96.

Shares of Hemispherx ended on Sep 6th at $1.96 and skyrocketed an extraordinary 4.26%. From a daily perspective, HEB is in a short term uptrend after plotting its last bottom ($1.78, on August/29) higher than the previous bottom, and its last top ($2.11, on Sep/5) also over the previous top. Now trading in between its last bottom and last top HEB might consolidate in a plain range, waiting to break out over $2.11 or down under $1.78.

HEB stock chart (daily)

Weekly outlook

After sliding a spooky -7.22% in a week late August, Hemispherx BioPharma closed this week at $1.96 and skyrocketed an outstanding 8.89%.

Since price and 20-weeks moving average lines crossed down by mid February, HEB fell $-8.16 per share (-80.63%).

HEB stock chart (weekly)

Hemispherx stock price history

Hemispherx IPO was on August 19th, 1996 at $1,914.00 per share1. Since then, HEB stock declined a -99.90%, with a yearly average of -4.30%.

1: Adjusted price after possible price splits or reverse-splits.

Hemispherx stock historical price chart

HEB stock reached 52-week highs on April at $14.96, and all-time highs 2000-03-02 with a price of 10032.

Hemispherx stock price target

How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not found any price prediction for Hemispherx stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

After posting its last earnings report on April, Hemispherx . Unfortunately, reported EPS is not yet available in our database.
HEB earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Hemispherx BioPharma annual sales plunged a bloodcurdling -16.02% to $0.37 M USD from $0.44 marked in 2017. When comparing 2018 vs 2017, aligned with this, profit margin (that is, the net income divided by revenues) plummed a -783.91% to -2,673.84%.

HEB annual Sales and Income evolution
2012$0.21 M-$-17.35 M-8145.5%-
2013$0.15 M-29.58%$-16.23 M-10820.0%-6.46%
2014$0.20 M31.33%$-17.45 M-8857.9%7.52%
2015$0.13 M-32.49%$-15.23 M-11451.1%-12.72%
2016$0.09 M-30.83%$-7.50 M-8154.3%-50.74%
2017$0.44 M375.00%$-8.26 M-1889.9%10.09%
2018$0.37 M-16.02%$-9.81 M-2673.8%18.82%

Quarterly financial results

Hemispherx BioPharma posted $0.24 million in sales for 2018-Q4, a 531.58% improvement compared to previous quarter. Reported quarter earnings marked $-1.61 M with a profit margin of -669.58%. Profit margin rocketed a 7,430.42% compared to previous quarter when profit margin was -8,100.00%. When comparing turnover to same quarter last year, Hemispherx sales marked an astounding growth and climbed a 380.00%. Looking back to recent quarterly results, Hemispherx posted 2 negative quarters in a row.
HEB quarterly Sales and Income evolution
2017-Q1$0.08 M-$-2.82 M-3357.1%-
2017-Q2$0.21 M153.57%$-2.19 M-1028.2%-22.34%
2017-Q3$0.09 M-57.75%$-1.25 M-1391.1%-42.83%
2017-Q4$0.05 M-44.44%$-1.99 M-3986.0%59.19%
2018-Q1$0.06 M12.00%$-2.71 M-4844.6%36.13%
2018-Q2$0.03 M-41.07%$-2.42 M-7318.2%-10.98%
2018-Q3$0.04 M15.15%$-3.08 M-8100.0%27.45%
2018-Q4$0.24 M531.58%$-1.61 M-669.6%-47.79%

Hemispherx ownership

When you are planning to buy a company, it's worth to overview its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Hemispherx BioPharma, 12.78% of all outstanding shares are owned by its staff.

In case of Hemispherx stock, 6.09% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for HEB stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Hemispherx BioPharma:

Market cap$0.5 M
Total shares0.3 M
Float shares2.0 M
  - Institutional holdings (%)6.1%
  - Insider holdings (%)12.8%
Shares in short selling0.0%

Hemispherx summary

Friday, September 6th, 2019
Day range$1.90 - $2.06
Previous close$1.88
Session gain4.26%
Average true range$0.19
50d mov avg$2.77
100d mov avg$4.33
200d mov avg$6.48
Daily patternlt06a
Weekly pattern lb06a

Hemispherx performance

To measure stock performance is always good to compare with competitors or related stocks. We compared Hemispherx against in the following table:
HEBHemispherx BioPha...-55.45%-70.30%-82.87%

Hemispherx competitors

Unfortunately, we could not find any public company that could be defined as Hemispherx BioPharma competitor. This doesn't mean Hemispherx BioPharma does not have any competitor in the market, it's just we could not detected it.